What is the role of dacomitinib in the treatment of non–small cell lung cancer (NSCLC)?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

Dacomitinib (Vizimpro) is an irreversible kinase inhibitor of the human EGFR family (EGFR/HER1, HER2, and HER4) and certain EGFR-activating mutations (exon 19 deletion or the exon 21 L858R substitution mutation). It is indicated for first-line treatment of patients with metastatic non-small lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

Approval of dacomitinib was based on the ARCHER 1050 trial (n=452). Dacomitinib was compared with gefitinib. The results showed a statistically significant improvement in progression-free survival (PFS) with dacomitinib: median PFS was 14.7 months with dacomitinib compared with 9.2 months with gefitinib (hazard ratio, 0.59; P < .0001). [166] Overall survival analysis showed slight improvement with dacomitinib 34.1 months compared with gefitinib 26.8 months. [167]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!